Stevanato Group SpA STVN

PIOMBINO DESE, Italy, September 08, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences:

On August 4, Stevanato Group (NYSE:STVN) reported second-quarter revenue of €302.0 million, up 8% year over year, while also closing the sale of its California-based subsidiary, Balda C. Brewer Inc. The results paired steady growth in the company’s core drug containment and delivery business with a portfolio move that reshaped its bottom line for the […]

Riverwater Partners, an investment management company, released its ‘Small Cap Strategy’ Q2 2026 investor letter. The letter can be downloaded here. The Small Cap Strategy underperformed the Russell 2000 in the second quarter as the benchmark experienced one of its strongest risk-on rallies in recent memory, although the strategy remained ahead year-to-date. The quarter was defined […]

What Stevanato Group’s latest earnings and guidance mean for investors Stevanato Group (STVN) has been in focus after its early August 2026 earnings report, which combined higher sales with lower net income, alongside updated full year revenue and earnings guidance. For the second quarter ended June 30, 2026, Stevanato Group reported sales of €302 million compared with €280.04 million a year earlier. Net income for the quarter was €22.96 million compared with €29.7 million in the prior year...

Stevanato Group S.p.A. recently reported past second-quarter 2026 results showing sales of €302 million with lower net income, slightly trimmed its full-year revenue guidance to €1.26–€1.28 billion, and outlined expected diluted EPS of €0.53–€0.55. At the same time, the company’s Alina pen injector platform secured European marketing authorizations for diabetes and weight-management combinations, highlighting Stevanato’s push into higher-value GLP-1 drug delivery solutions. We’ll now examine...

Stevanato Group stock has declined 34.6% over the past three years, and current checks send mixed valuation signals, with an intrinsic value estimate suggesting the shares trade at a discount while market multiples point to a richer price tag. Stevanato Group has fallen 34.6% over three years, which puts extra focus on whether the current share price still reflects the long term potential of its drug delivery and packaging business. Commercial progress for the Alina pen injector platform in...

Moby summary of Stevanato Group S.p.A.'s Q2 2026 earnings call

Stevanato Group SpA (STVN) reports 8% revenue growth, 280 bps EBITDA margin expansion, and a key European regulatory milestone for its Alina pen platform.

ANAHEIM, CA / ACCESS Newswire / August 4, 2026 /Craftech Holdco, a portfolio company of Sage Park, today announced the acquisition of Balda C. Brewer ("BCB"), the Ontario, California-based contract manufacturing subsidiary, from its parent company, ...

PIOMBINO DESE, Italy, August 04, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026.

PIOMBINO DESE, Italy, July 30, 2026--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketi

Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of +51.69% and +40.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?